Salient Surgical Technologies reaches key milestone of 500,000 patients treated with TRANSCOLLATION® Technology

PORTSMOUTH, N.H.--(BUSINESS WIRE)-- Salient Surgical Technologies, Inc., has announced the achievement of a key milestone in the company’s history – treatment of the 500,000th patient using its patented TRANSCOLLATION technology, which enables surgeons to stop intra-operative bleeding during their procedures and reduce blood loss for patients following surgery.

The 500,000th device was purchased by Kendall Regional Medical Center in Miami, Florida, a community health care provider where Salient’s technology is used regularly in the Orthopedic & Spine Institute. Kendall has treated patients in the West Miami-Dade community since 1973 and recently received for the fifth year in a row the Healthgrades Distinguished Hospital for Clinical Excellence Award.

“We’ve been helping surgeons all over the world effectively manage blood loss in their patients for more than ten years,” said Joseph F. Army, President and CEO of Salient. “Treating half a million patients is truly an exciting landmark for us, and it’s another step toward our goal of becoming standard of care.”

Salient’s TRANSCOLLATION technology combines radiofrequency (RF) energy and saline to provide hemostatic sealing of soft tissue and bone during surgery. Studies have shown that the company’s AQUAMANTYS® System, which uses TRANSCOLLATION technology, significantly reduces blood loss during surgery and the need for post-operative blood transfusions in patients.

Blood transfusions are common after procedures such as hip and knee replacements if patients experience low hemoglobin levels. They have been linked to longer hospital stays, lengthier recovery times and even post-operative infections.

“We have a great product to offer the healthcare industry,” said Salient Vice President of Sales John Hironimus, who presented special commemorative plaques to the hospital and to Drs. Pablo J. Acebal and Pedro J. Carvajal, both regular users of the AQUAMANTYS System. “Reaching this landmark is further proof that doctors see the value TRANSCOLLATION technology provides, not only to them as they perform the procedure but also to their patients during the surgery and after it’s done.”

Devices utilizing TRANSCOLLATION technology are currently used in orthopedic reconstruction, spine surgery, brain tumor resection, trauma procedures and surgical oncology.

About Salient Surgical Technologies

Salient Surgical Technologies, Inc. (www.salientsurgical.com) is a medical technology company that develops and markets advanced energy devices for use in surgical procedures. Salient's proprietary TRANSCOLLATION® technology provides hemostatic sealing of soft tissue and bone, allowing surgeons to rapidly treat tissue at the surgical site to reduce blood loss and improve patient outcomes. Salient's products are currently used in orthopedic reconstruction, spine surgery, brain tumor resection, trauma procedures and surgical oncology.



CONTACT:

Salient Surgical Technologies, Inc.
Jennifer Silverman, 603-742-1515
Director, Marketing Communications
[email protected]

KEYWORDS:   United States  North America  New Hampshire

INDUSTRY KEYWORDS:   Surgery  Health  Biotechnology  Hospitals  Medical Devices  Oncology  Medical Supplies

MEDIA:

Logo
 Logo

Suggested Articles

The profit margins and management of Community Health Group raise questions about oversight of managed care insurers.

Financial experts are warning practices about the pitfalls of promoting medical credit cards to their patients.

A proposed rule issued by HHS on Tuesday would expand short-term coverage, a move Seema Verma said will have "virtually no impact" on ACA premiums.